Hot Mandate : New York VC Firm Invests in US-Based Early to Mid-Stage Medical Device Companies

1 Oct

A venture capital firm based in New York is seeking to make seed, venture, and growth equity investments in early to mid-stage medical device companies. The firm can allocate anywhere from $1M to $10M per company, but generally allocates around $8M. The firm typically does 3 rounds of financing with an initial investment of around $3M. The firm is geographically agnostic, but highly prefers to invest in companies that are based in the US. The firm seeks to make about 3-4 allocations in the next 6-9 months.

The firm is currently looking for medical device companies with a strong emphasis on products with a 510(k) regulatory pathway. In terms of subsectors, the firm is looking for products specifically in the areas of interventional radiology and cardiology, spine/orthopedics and minimally invasive surgery. The firm is generally opportunistic in terms of indication.

The firm is looking to invest in companies with a management team with a track record of success in the healthcare industry. However, the firm is generally flexible and does not require a full management team. The firm can assemble the management team over the course of the investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Mandate: Singapore VC Firm Invests Globally in Novel Medical Device, Therapeutics, Diagnostics and Digital Health Companies

1 Oct

A venture capital firm was founded in 2005 with headquarters in Singapore and Shanghai, with additional offices in Hong Kong, New York, and San Diego. The firm closed fifth fund, Fund V, of over $220M and is actively seeking investment opportunities across a wide range of industries. 1/3 of the fund is dedicated to global/USA-based life sciences and healthcare investments, while the rest of the fund will focus on investing in China and Southeast Asia-based companies. On average, the initial size of investment is in the $2-5M range but the firm has the capacity to invest more in companies they identify as a strong fit. The firm can participate anywhere from Seed to Series B, but Series A is their sweet spot.

The firm is an opportunistic investor and will consider therapeutics, medical devices, diagnostics, and healthcare IT companies. However, the firm will generally avoid single therapeutic assets and those that are pre-clinical or earlier. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in platform plays, or technologies that have implications in multiple disease areas or indications.

The firm considers the management team’s character and entrepreneurial spirit – more so than the team’s experience – as one of the most important factors in the investment screening process. Each partner of the firm will dedicate their time to become acquainted with the management team and determine their degree of fit. The targeted market and the company’s competitive edge are also important considerations. The firm prefers to act as the lead investor and will seek board representation, but is also open to co-investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Mandate: Boston Based Family Office Seeks US-Based Healthcare IT, Medical Devices and Diagnostics

1 Oct

A family office based in Boston, Massachusetts is currently interested in investing into privately held companies in the life science space. The firm is very flexible and nimble due to its capital base and is able to make investments ranging anywhere from $500,000 to $20 million and more into a given company. The firm is currently looking for companies located throughout the United States. The firm generally would only act as a co-investor from companies located outside the United States.

The firm is open to sectors and subsectors in the life science space including Health Care IT, Medical Devices, Diagnostics. For devices and diagnostics, the firm is looking for companies that have significant clinical data. Current portfolio companies include those working with antiviral therapies, cloud-based laboratory services, anticoagulant therapies, orthotics and prosthetics, medical devices and diagnostics for male lower urinary tract symptoms, and therapeutics for dermatology and aesthetics.

The firm is looking for companies with experienced management teams and generally looks to take a board seat following investment. Due to the firm’s capital base they can be more flexible in terms of investment timeframe and have a longer exit horizon than other investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Mandate: Chinese VC Firm with USD and RMB Funds Invests in Global Opportunities with China Angle

1 Oct

A venture capital firm based in Shanghai, China currently manages two angel funds including RMB Fund I and Fund II, with a venture USD fund. On average, the initial size of investment is in the $1-6M range, but the firm has the capacity to invest more in companies they identify as a strong fit. The firm has multiple innovation centers across China focusing on different special areas in Life Sciences and Healthcare. With operating experience of international medical technology incubators, the firm looks to tailor its services to help portfolio companies reaching key value-added milestones. The firm will consider opportunities based in China and around the globe, companies within a strong China angle involvement is their sweet spot.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, Healthcare IT, and Biotechnology R&D Services. The firm is opportunistic in terms of subsector and indication and is willing to consider companies targeting orphan indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. In terms of therapeutics, the firm will look at products in pre-clinical stages. Regarding medical devices and diagnostics, the firm will invest at any stage of development.

The firm can participate as either lead or co-investor, and may take a board seat in applicable cases. The firm has no specific requirements for the management team. Team members who speak Mandarin may be a plus but are not required.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

LSN Launches Healthtech Partnering Week, Partners with Mary Furlong & Associates on New Longevity Partnering Event

24 Sep

By Rory McCann, Marketing Manager & Conference Producer, LSN

The Inaugural Life Science Nation (LSN) Healthtech Partnering Week 2021 launches January 11-15, 2021 with three back-to-back digital partnering conferences: Redefining Early Stage Investments (RESI), 4D Meets AI, and Longevity, Health & Innovation (LHI). LSN’s RESI conference series has been very successful co-located with the J.P. Morgan Annual Healthcare Conference and will continue to grow with its two newest digital partnering conferences as a healthcare event trifecta.

LSN is proud to announce the newest digital partnering conference, Longevity, Health & Innovation, co-organized with Mary Furlong & Associates, the preeminent leader in the longevity education market. While Covid has ravaged the conference and event industry, LSN has seen tremendous growth in early-stage partnerships throughout life science and healthcare and looks forward to expanding through the week-long partnering event. The need to connect buyers and sellers is greater than ever, and LSN is proud to partner with Mary Furlong & Associates to facilitate these conversations in the longevity market.

Learn more about the three events:

Redefining Early-Stage Investments (RESI) – January 11-13, 2021

The Redefining Early Stage Investments (RESI) conference series was created by Life Science Nation (LSN) to bring together startups with early-stage investors and strategic channel partners to maximize the capability of these companies, from seed to series B, to find partners who are a fit for their technology and stage of development. RESI is cross-border and cross-domain, connecting start-ups with ten categories of global investors across the silos of drugs, devices, diagnostics, and digital health. RESI caters to both the earliest stage start-ups, those seeking grants, seed and angel capital, and the early-stage firms who seek series A and B funding.

4D Meets AI (4D) – January 14-15, 2021

Artificial intelligence (AI) is rapidly reshaping the healthcare landscape, and redefining what is possible in life science. The business of AI is broken down into two groups: the buyers and the sellers. 4D Meets AI is a partnering conference that connects the investors and strategic partners and matches them to companies developing and commercializing AI technology in drugs, devices, diagnostics, and digital health (the 4 Ds) to revolutionize healthcare. In addition to pitch sessions and one-on-one meetings hosted by our premier partnering platform, 4D Meets AI features investor and application panels to expand your knowledge of the industry and learn the latest trends and developments. This two-day digital conference provides the opportunity to meet strategic partners, learn from the experts, and build relationships to advance the future of healthcare.

Longevity, Health & Innovation (LHI), Co-Organized with Mary Furlong & Associates – January 14-15, 2021

The aging boomer population contributed $8.3 trillion in economic activity to the 2018 US economy, and that number is projected to triple by 2050. The need for advancements in drugs, devices, diagnostics, and digital health for the treatment of age-related conditions is crucial. Longevity, Health & Innovation (LHI) is a new partnering conference focused on conditions related to aging, market challenges, and solutions via early-stage companies and their promising tech and products. LHI brings fundraising startups together with investors in longevity innovation to make deals in order that today’s seniors live longer, healthier lives.

Announcing Digital RESI November Panels

24 Sep

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claire

Life Science Nation (LSN) is pleased to announce its newest Digital RESI taking place November 17-19, 2020. Digital RESI is a powerful gathering focused on early-stage funding across all verticals of life science: drugs, devices, diagnostics, digital health. Attendees can meet with hundreds of investors and strategic partners from five continents over three days using RESI’s unique partnering platform, which identifies targets based on best fit for your technology and stage of development.

RESI is building on the success of Digital RESI September and keeping the conversations going beyond partnering with a new lineup of live panels. Check out the panels and descriptions and save $150 on registration with super early bird discount code: SUPEREBNOV.

EARLY STAGE THERAPEUTICS INVESTORS
Bringing the Newest Therapies to the Clinic
This panel aims to bring a diverse group of experts & senior decision making staff from VCs, corporate pharma, and other investor types together to discuss topics such as:
  • How they make decisions
  • What can startups do to be more attractive?
  • Areas of high need
  • Overcrowded areas
  • Common mistakes/red flags
The moderator will guide the discussion through topics including how the investors source & vet novel therapeutic assets, what kinds of technology are of interest to them right now, and how they as investors work with a startup to move a new drug toward commercialization.
MEDICAL DEVICE INVESTORS
Investing in Novel Engineering
 This panel focuses on investment in new medical devices from development stage through to early commercialization. Topics may include:

  • What are investors looking for?
  • Areas of interest
  • Overcrowded areas
  • How to approach an investor
  • Successful deals they’ve done before
  • Common mistakes/Red flags

Panelists will discuss how to meet the challenges of raising financing for a new device and advise startups on how to make the investment case for their novel technology. Panelists will also explore what technology areas are of top interest to them and how a startup can get them into dialogue regarding an investment or deal.
DIAGNOSTICS INVESTORS
New Generation of Technologies Changing Treatment Paradigms
This panel focuses on investments in innovative diagnostics, ranging from IVD, genomics, precision medicine, and more. Topics may include:
  • Current areas of interest
  • Current challenges in this ecosystem – Navigating the competitive landscape
  • Commonly observed red flags
  • Successful deals
Panelists will discuss how companies can successfully fundraise for their budding diagnostics technology and the best way to successfully approach and develop a relationship with relevant investors. Panelists will also explore current areas of interest and why they are relevant, as well as developmental and regulatory hurdles and how companies can address these problems to attain key milestones.
DIGITAL HEALTH
Leveraging Software to Lower Costs and Improve the Quality of Care
This panel focuses on investing in innovative digital health products that bring new efficiencies to the healthcare system, change how care is delivered or managed, and how patients are involved in their own care. Panelists will explore topics related to investing in digital health, including:
  • In what kinds of digital health technologies are they interested in investing?
  • What metrics and evidence do you look for in a digital health startup?
  • How can an early stage digital health company demonstrate the value of their products?
  • What are the main challenges for startups raising capital in this space?
The moderator and panelists will discuss this rapidly evolving field of healthcare investment, and will introduce the audience to the key fundraising opportunities and challenges facing digital health entrepreneurs today.
CORPORATE VENTURE CAPITAL
The Corporate Landscape Morphed & New Opportunities Abound
This panel discusses what strategies are employed by corporate venture capital firms for investments and partnerships with early-stage companies. Potential topics for the panel include:
  • What corporate VCs look for in companies
  • What working with a corporate VC entails
  • What companies should do to be relevant to the corporate VC
Panelists could also discuss the relationship between the corporate venture capital firm and the parent company and how it affects investment criteria.
FAMILY OFFICES & ANGELS
How Do Family Offices View Seed & Series A Rounds?
When Life Science Nation (LSN) first launched the Redefining Early Stage Investments Conference Series (RESI), we focused on bringing investors from beyond venture capital to meet face to face with entrepreneurs. Angels and family offices are two of these alternative sources of early stage capital. These investor types are distinct from each other in many ways but also work well together. The Angels & Family Offices panel will introduce RESI’s entrepreneurs to these distinctions and also the ways in which these private capital pools are working together to fund healthcare innovation.
  • What do Angels and Family Offices have in common?
  • How do Angels and Family Offices plan their investment horizons?
  • Are Angels and Family Offices looking at the same sectors and opportunities as VCs?

Digital RESI Format Delivers Promising Results

24 Sep

By Gregory Mannix, Chief Conference Officer, Vice President International Business Development, LSN

Life Science Nation (LSN) was preparing for RESI Europe to take place on March 23, 2020 in Paris when the world turned upside-down. Like so many across the globe clamoring to pivot with the changing tides, LSN had to make an unprecedented decision to either cancel the conference or pivot to a digital format with only two weeks’ notice.

At the time, it remained unclear if the core value of the RESI conference series—making meaningful connections through partnering meetings and investor and workshop panels—would be feasible in a digitally delivered conference, but the benefits far outweighed the challenges. The result exceeded even the most optimistic projections as the team worked to transform a regional European event into a truly global event, with participants representing five continents, many of whom would not have traveled to Paris, regardless of the global pandemic. The transition to the digital format has broken down barriers and reduced travel costs in a meaningful way, making the Digital RESI events more accessible than ever. Since March, there have been five Digital RESI events yielding promising trends.

The transition to Digital RESI has enabled the enhancement of the partnering platform, creating many more meeting slots to facilitate meetings among participants from different countries and time zones, mirroring the cross-border industry trends this year. The chart below represents an increase in both the percentage of meetings accepted at the Digital RESI conferences as compared to the pre-pandemic on-site conferences, as well as in the average total number of meetings taking place at each conference.

This encouraging example of adaptation and resilience in the early-stage life science industry bodes well for the future of deal-making across drugs, devices, diagnostics, and digital health. LSN is proud to be a part of the process in a time where these deals have the potential to truly change the world.

← Older Entries
Newer Entries →